Klebsiella pneumonia

Summary

Klebsiella pneumonia (MONDO:0030602) is a disease and 5 clinical trials. Top therapeutic interventions include nitrofurantoin. A subtype of bacterial pneumonia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Klebsiella pneumonia
Mondo ID	MONDO:0030602
DOID	DOID:13272
ICD-10-CM	J15.0
SNOMED CT	64479007
UMLS	C0519030
MedGen	636012
Is cancer (heuristic)	no

Also known as: Klebsiella caused pneumonia · pneumonia due to Klebsiella pneumoniae

Disease family

This is a subtype of bacterial pneumonia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › bacterial pneumonia › Klebsiella pneumonia

Related subtypes (7): anaerobic pneumonia, Legionnaires’ disease, Mycoplasma pneumoniae pneumonia, staphylococcal pneumonia, streptococcal pneumonia, pneumonia caused by pseudomonas aeruginosa infection, pneumonia caused by gram negative bacteria

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06815549	PHASE3	NOT_YET_RECRUITING	An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis
NCT01324726	Not specified	COMPLETED	Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms
NCT03094494	Not specified	COMPLETED	Double Carbapenem as Rescue Strategy for the Treatment of Carbapenemase-Producing Klebsiella Pneumoniae Infections
NCT03597841	Not specified	COMPLETED	Turkish Prospective Cohort Study on Carbapenem Resistant Klebsiella Pneumonia Bacteremia
NCT05880069	Not specified	UNKNOWN	Clinical Outcomes in Patients With Infection by Resistant Microorganism

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
NITROFURANTOIN	4	1